Bernd Schmidt
Chief Tech/Sci/R&D Officer chez SENSORION
Profil
Bernd Schmidt is currently the Chief Technical Officer at Sensorion SA since 2023.
Prior to this, he worked as the Vice President-Product Delivery at Quell Therapeutics Ltd.
Mr. Schmidt is a graduate of Friedrich-Alexander University of Erlangen-Nuremberg.
Postes actifs de Bernd Schmidt
| Sociétés | Poste | Début |
|---|---|---|
| SENSORION | Chief Tech/Sci/R&D Officer | 11/12/2023 |
Anciens postes connus de Bernd Schmidt
| Sociétés | Poste | Fin |
|---|---|---|
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Formation de Bernd Schmidt
| Friedrich-Alexander University of Erlangen-Nuremberg | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SENSORION | Health Technology |
| Entreprise privées | 1 |
|---|---|
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Health Technology |
